Mylan, Pfizer each denied a motion in generic Norvasc case

NEW YORK (AFX) -- Mylan Laboratories Inc., the Pittsburgh drugmaker, said a federal court denied Pfizer Inc.'s effort to dismiss Mylan's inequitable-conduct claims in the companies' amlodipine besylate patent litigation. Amlodipine besylate is the generic version of Pfizer's Norvasc treatment for high blood pressure. The U.S. District Court for the Western District of Pennsylvania also denied Mylan's motion

to invalidate one of the patents in the case.

This story was supplied by MarketWatch. For further information see www.marketwatch.com.

For more information and to contact AFX: www.afxnews.com and www.afxpress.com